Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Leukemia

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 67 articles: HTML format

Single Articles

March 2023
1. TONG WH, Mertens BJ
   More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?
   J Clin Oncol. 2023 Mar 10:JCO2202839. doi: 10.1200/JCO.22.02839.
   PubMed    
   
   
   
2. VAN DE DONK NWCJ
   How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells.
   J Clin Oncol. 2023;41:1342-1349.
   PubMed     Abstract available
   
   
   February 2023
3. FARRAR JE, Smith JL, Othus M, Huang BJ, et al
   Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia.
   J Clin Oncol. 2023 Feb 16:JCO2201114. doi: 10.1200/JCO.22.01114.
   PubMed     Abstract available
   
   
   January 2023
4. CRIVELLO P, Arrieta-Bolanos E, He M, Wang T, et al
   Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation.
   J Clin Oncol. 2023 Jan 20:JCO2201229. doi: 10.1200/JCO.22.01229.
   PubMed     Abstract available
   
   
   
5. SMYTH E, Eyre TA, Cheah CY
   Emerging Therapies for the Management of Richter Transformation.
   J Clin Oncol. 2023;41:395-409.
   PubMed     Abstract available
   
   
   
6. SHIBUSAWA M, Tanimoto T
   Conditioning Regimen in Patients With Adult Acute B Lymphoblastic Leukemia.
   J Clin Oncol. 2023 Jan 3:JCO2202230. doi: 10.1200/JCO.22.02230.
   PubMed    
   
   
   December 2022
7. ITZYKSON R, Santini V, Thepot S, Ades L, et al
   Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
   J Clin Oncol. 2022 Dec 1:JCO2200437. doi: 10.1200/JCO.22.00437.
   PubMed     Abstract available
   
   
   November 2022
8. LAETSCH TW, Maude SL, Rives S, Hiramatsu H, et al
   Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
   J Clin Oncol. 2022 Nov 18:JCO2200642. doi: 10.1200/JCO.22.00642.
   PubMed     Abstract available
   
   
   
9. HILLMEN P, Eichhorst B, Brown JR, Lamanna N, et al
   Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
   J Clin Oncol. 2022 Nov 17:JCO2200510. doi: 10.1200/JCO.22.00510.
   PubMed     Abstract available
   
   
   
10. CASEY M, Odhiambo L, Aggarwal N, Shoukier M, et al
    Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?
    J Clin Oncol. 2022;40:3719-3729.
    PubMed     Abstract available
    
    
    
11. WANG T, Tang Y, Cai J, Wan X, et al
    Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
    J Clin Oncol. 2022 Nov 8:JCO2201214. doi: 10.1200/JCO.22.01214.
    PubMed     Abstract available
    
    
    
12. JACOLA LM, Conklin HM, Krull KR, Pei D, et al
    The Impact of Intensified CNS-Directed Therapy on Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated Without Cranial Irradiation.
    J Clin Oncol. 2022 Nov 2:JCO2200263. doi: 10.1200/JCO.22.00263.
    PubMed     Abstract available
    
    
    October 2022
13. GROB T, Sanders MA, Vonk CM, Kavelaars FG, et al
    Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Oct 31:JCO2200715. doi: 10.1200/JCO.22.00715.
    PubMed     Abstract available
    
    
    
14. JELINEK T, Bezdekova R, Zihala D, Sevcikova T, et al
    More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
    J Clin Oncol. 2022 Oct 31:JCO2201226. doi: 10.1200/JCO.22.01226.
    PubMed     Abstract available
    
    
    
15. LAMPSON BL, Gupta A, Tyekucheva S, Mashima K, et al
    Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2022 Oct 31:JCO2200269. doi: 10.1200/JCO.22.00269.
    PubMed     Abstract available
    
    
    
16. ATTARBASCHI A, Moricke A, Harrison CJ, Mann G, et al
    Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study.
    J Clin Oncol. 2022 Oct 18:JCO2201297. doi: 10.1200/JCO.22.01297.
    PubMed     Abstract available
    
    
    September 2022
17. SCHULTZ LM, Eaton A, Baggott C, Rossoff J, et al
    Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2022 Sep 15:JCO2201076. doi: 10.1200/JCO.22.01076.
    PubMed     Abstract available
    
    
    
18. ZHANG H, Fan Z, Huang F, Han L, et al
    Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.
    J Clin Oncol. 2022 Sep 9:JCO2200767. doi: 10.1200/JCO.22.00767.
    PubMed     Abstract available
    
    
    August 2022
19. SOCIE G
    Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia.
    J Clin Oncol. 2022 Aug 5:JCO2201177. doi: 10.1200/JCO.22.01177.
    PubMed     Abstract available
    
    
    July 2022
20. DAVER N, Perl AE, Maly J, Levis M, et al
    Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Jul 18:JCO2200602. doi: 10.1200/JCO.22.00602.
    PubMed     Abstract available
    
    
    
21. MISHRA A, Tamari R, DeZern AE, Byrne MT, et al
    Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    J Clin Oncol. 2022 Jul 11:JCO2200181. doi: 10.1200/JCO.22.00181.
    PubMed     Abstract available
    
    
    June 2022
22. ARMENIAN SH, Chen Y, Hageman L, Wu J, et al
    Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study.
    J Clin Oncol. 2022 Jun 22:JCO2102829. doi: 10.1200/JCO.21.02829.
    PubMed     Abstract available
    
    
    
23. MOORMAN AV, Antony G, Wade R, Butler ER, et al
    Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial.
    J Clin Oncol. 2022 Jun 17:JCO2200245. doi: 10.1200/JCO.22.00245.
    PubMed     Abstract available
    
    
    
24. KADIA TM, Reville PK, Wang X, Rausch CR, et al
    Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Jun 15:JCO2102823. doi: 10.1200/JCO.21.02823.
    PubMed     Abstract available
    
    
    
25. HANTEL A, Kohlschmidt J, Eisfeld AK, Stock W, et al
    Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.
    J Clin Oncol. 2022 Jun 13:JCO2200307. doi: 10.1200/JCO.22.00307.
    PubMed     Abstract available
    
    
    
26. CHIHARA D, Huang EP, Finnigan SR, Cordes LM, et al
    Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
    J Clin Oncol. 2022;40:1949-1957.
    PubMed     Abstract available
    
    
    May 2022
27. PASQUAL E, Schonfeld S, Morton LM, Villoing D, et al
    Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    J Clin Oncol. 2022;40:1439-1449.
    PubMed     Abstract available
    
    
    April 2022
28. PERL AE
    Pediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 Inhibition.
    J Clin Oncol. 2022 Apr 18:JCO2200499. doi: 10.1200/JCO.22.00499.
    PubMed    
    
    
    
29. CHANG A, Akhtar A, Linderman SL, Lai L, et al
    Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2022 Apr 18:JCO2200088. doi: 10.1200/JCO.22.00088.
    PubMed     Abstract available
    
    
    
30. BLEAKLEY M, Sehgal A, Seropian S, Biernacki MA, et al
    Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.
    J Clin Oncol. 2022;40:1174-1185.
    PubMed     Abstract available
    
    
    
31. WALSH BS, Kesselheim AS, Sarpatwari A, Rome BN, et al
    Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling.
    J Clin Oncol. 2022;40:1102-1110.
    PubMed     Abstract available
    
    
    March 2022
32. HOFSTE OP BRUININK D, Kuiper R, van Duin M, Cupedo T, et al
    Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
    J Clin Oncol. 2022 Mar 31:JCO2101217. doi: 10.1200/JCO.21.01217.
    PubMed     Abstract available
    
    
    
33. POLLARD JA, Alonzo TA, Gerbing R, Brown P, et al
    Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.
    J Clin Oncol. 2022 Mar 29:JCO2101612. doi: 10.1200/JCO.21.01612.
    PubMed     Abstract available
    
    
    
34. MYERS RM, Taraseviciute A, Steinberg SM, Lamble AJ, et al
    Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    J Clin Oncol. 2022;40:932-944.
    PubMed     Abstract available
    
    
    
35. TEACHEY DT, Devidas M, Wood BL, Chen Z, et al
    Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    J Clin Oncol. 2022 Mar 10:JCO2102678. doi: 10.1200/JCO.21.02678.
    PubMed     Abstract available
    
    
    February 2022
36. ADVANI AS, Moseley A, O'Dwyer KM, Wood BL, et al
    SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2022 Feb 14:JCO2101766. doi: 10.1200/JCO.21.01766.
    PubMed     Abstract available
    
    
    January 2022
37. JORDHEIM LP
    Toward Personalization of Cytarabine Dosing in Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Jan 13:JCO2102723. doi: 10.1200/JCO.21.02723.
    PubMed    
    
    
    
38. O'BRIEN MM, Ji L, Shah NN, Rheingold SR, et al
    Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
    J Clin Oncol. 2022 Jan 10:JCO2101693. doi: 10.1200/JCO.21.01693.
    PubMed     Abstract available
    
    
    
39. DINARDO CD, Pollyea DA
    Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy.
    J Clin Oncol. 2022 Jan 10:JCO2102762. doi: 10.1200/JCO.21.02762.
    PubMed    
    
    
    
40. GIBSON CJ, Kim HT, Zhao L, Murdock HM, et al
    Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
    J Clin Oncol. 2022;40:189-201.
    PubMed     Abstract available
    
    
    
41. ELSAYED AH, Cao X, Mitra AK, Wu H, et al
    Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    J Clin Oncol. 2022 Jan 6:JCO2101422. doi: 10.1200/JCO.21.01422.
    PubMed     Abstract available
    
    
    December 2021
42. PRATZ KW, Jonas BA, Pullarkat V, Recher C, et al
    Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine.
    J Clin Oncol. 2021 Dec 15:JCO2101546. doi: 10.1200/JCO.21.01546.
    PubMed     Abstract available
    
    
    
43. NORSWORTHY KJ, Gao X, Ko CW, Pulte ED, et al
    Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
    J Clin Oncol. 2021 Dec 10:JCO2101548. doi: 10.1200/JCO.21.01548.
    PubMed     Abstract available
    
    
    
44. SCHULTZ LM, Baggott C, Prabhu S, Pacenta HL, et al
    Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
    J Clin Oncol. 2021 Dec 9:JCO2003585. doi: 10.1200/JCO.20.03585.
    PubMed     Abstract available
    
    
    
45. LAMBLE AJ, Eidenschink Brodersen L, Alonzo TA, Wang J, et al
    CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2021 Dec 2:JCO2101595. doi: 10.1200/JCO.21.01595.
    PubMed     Abstract available
    
    
    October 2021
46. NAKAMURA R, Saber W, Martens MJ, Ramirez A, et al
    Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
    J Clin Oncol. 2021;39:3328-3339.
    PubMed     Abstract available
    
    
    
47. WIERDA WG, Allan JN, Siddiqi T, Kipps TJ, et al
    Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    J Clin Oncol. 2021 Oct 7:JCO2100807. doi: 10.1200/JCO.21.00807.
    PubMed     Abstract available
    
    
    
48. POLLARD JA, Guest E, Alonzo TA, Gerbing RB, et al
    Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
    J Clin Oncol. 2021;39:3149-3160.
    PubMed     Abstract available
    
    
    August 2021
49. RODDIE C, Dias J, O'Reilly MA, Abbasian M, et al
    Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2021 Aug 31:JCO2100917. doi: 10.1200/JCO.21.00917.
    PubMed     Abstract available
    
    
    
50. ABDEL-QADIR H, Sabrie N, Leong D, Pang A, et al
    Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
    J Clin Oncol. 2021 Aug 31:JCO2100693. doi: 10.1200/JCO.21.00693.
    PubMed     Abstract available
    
    
    
51. SHORT NJ, Kantarjian H
    When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era.
    J Clin Oncol. 2021 Aug 18:JCO2100960. doi: 10.1200/JCO.21.00960.
    PubMed    
    
    
    July 2021
52. PAN J, Tan Y, Wang G, Deng B, et al
    Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
    J Clin Oncol. 2021 Jul 29:JCO2100389. doi: 10.1200/JCO.21.00389.
    PubMed     Abstract available
    
    
    
53. STEPHENS DM
    Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?
    J Clin Oncol. 2021 Jul 26:JCO2101414. doi: 10.1200/JCO.21.01414.
    PubMed    
    
    
    
54. BYRD JC, Hillmen P, Ghia P, Kater AP, et al
    Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
    J Clin Oncol. 2021 Jul 26:JCO2101210. doi: 10.1200/JCO.21.01210.
    PubMed     Abstract available
    
    
    
55. GUI G, Dillon LW, Hourigan CS
    Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy.
    J Clin Oncol. 2021;39:2413-2415.
    PubMed    
    
    
    
56. VROOMAN LM, Blonquist TM, Stevenson KE, Supko JG, et al
    Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
    J Clin Oncol. 2021 Jul 6:JCO2003692. doi: 10.1200/JCO.20.03692.
    PubMed     Abstract available
    
    
    June 2021
57. DESAI PM, Brown J, Gill S, Solh MM, et al
    Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
    J Clin Oncol. 2021 Jun 22:JCO2001739. doi: 10.1200/JCO.20.01739.
    PubMed     Abstract available
    
    
    
58. MYERS RM, Li Y, Barz Leahy A, Barrett DM, et al
    Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2021 Jun 22:JCO2003458. doi: 10.1200/JCO.20.03458.
    PubMed     Abstract available
    
    
    
59. WEI AH, Roboz GJ, Kantarjian HM
    Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia.
    J Clin Oncol. 2021 Jun 4:JCO2100080. doi: 10.1200/JCO.21.00080.
    PubMed    
    
    
    
60. ZHENG H, Jiang H, Hu S, Liao N, et al
    Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.
    J Clin Oncol. 2021 Jun 2:JCO2003096. doi: 10.1200/JCO.20.03096.
    PubMed     Abstract available
    
    
    May 2021
61. SHORT NJ, Tallman MS, Pollyea DA, Ravandi F, et al
    Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape.
    J Clin Oncol. 2021 May 27:JCO2100067. doi: 10.1200/JCO.21.00067.
    PubMed    
    
    
    
62. DINARDO CD, Lachowiez CA, Takahashi K, Loghavi S, et al
    Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
    J Clin Oncol. 2021 May 27:JCO2003736. doi: 10.1200/JCO.20.03736.
    PubMed     Abstract available
    
    
    
63. SHAH NN, Lee DW, Yates B, Yuan CM, et al
    Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
    J Clin Oncol. 2021;39:1650-1659.
    PubMed     Abstract available
    
    
    April 2021
64. SHAW BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, et al
    National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
    J Clin Oncol. 2021 Apr 27:JCO2003502. doi: 10.1200/JCO.20.03502.
    PubMed     Abstract available
    
    
    
65. VAN DER PLAS E, Modi AJ, Li CK, Krull KR, et al
    Cognitive Impairment in Survivors of Pediatric Acute Lymphoblastic Leukemia Treated With Chemotherapy Only.
    J Clin Oncol. 2021 Apr 22:JCO2002322. doi: 10.1200/JCO.20.02322.
    PubMed    
    
    
    February 2021
66. RIMANDO JC, Christopher MJ, Rettig MP, DiPersio JF, et al
    Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.
    J Clin Oncol. 2021;39:386-396.
    PubMed    
    
    
    
67. PETERS C, Dalle JH, Locatelli F, Poetschger U, et al
    Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
    J Clin Oncol. 2021;39:295-307.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: